Literature DB >> 15208206

Patterns of treatment effects in subsets of patients in clinical trials.

Marco Bonetti1, Richard D Gelber.   

Abstract

We discuss the practice of examining patterns of treatment effects across overlapping patient subpopulations. In particular, we focus on the case in which patient subgroups are defined to contain patients having increasingly larger (or smaller) values of one particular covariate of interest, with the intent of exploring the possible interaction between treatment effect and that covariate. We formalize these subgroup approaches (STEPP: subpopulation treatment effect pattern plots) and implement them when treatment effect is defined as the difference in survival at a fixed time point between two treatment arms. The joint asymptotic distribution of the treatment effect estimates is derived, and used to construct simultaneous confidence bands around the estimates and to test the null hypothesis of no interaction. These methods are illustrated using data from a clinical trial conducted by the International Breast Cancer Study Group, which demonstrates the critical role of estrogen receptor content of the primary breast cancer for selecting appropriate adjuvant therapy. The considerations are also relevant for general subset analysis, since information from the same patients is typically used in the estimation of treatment effects within two or more subgroups of patients defined with respect to different covariates.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15208206     DOI: 10.1093/biostatistics/5.3.465

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  65 in total

1.  A Simple Method for Estimating Interactions between a Treatment and a Large Number of Covariates.

Authors:  Lu Tian; Ash A Alizadeh; Andrew J Gentles; Robert Tibshirani
Journal:  J Am Stat Assoc       Date:  2014-10       Impact factor: 5.033

2.  Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.

Authors:  S Aebi; Z Sun; D Braun; K N Price; M Castiglione-Gertsch; M Rabaglio; R D Gelber; D Crivellari; J Lindtner; R Snyder; P Karlsson; E Simoncini; B A Gusterson; G Viale; M M Regan; A S Coates; A Goldhirsch
Journal:  Ann Oncol       Date:  2011-01-31       Impact factor: 32.976

3.  Analysis of randomized comparative clinical trial data for personalized treatment selections.

Authors:  Tianxi Cai; Lu Tian; Peggy H Wong; L J Wei
Journal:  Biostatistics       Date:  2010-09-28       Impact factor: 5.899

4.  Using clinical trial data to tailor adjuvant treatments for individual patients.

Authors:  Meredith M Regan; Richard D Gelber
Journal:  Breast       Date:  2007-08-23       Impact factor: 4.380

5.  A small sample study of the STEPP approach to assessing treatment-covariate interactions in survival data.

Authors:  Marco Bonetti; David Zahrieh; Bernard F Cole; Richard D Gelber
Journal:  Stat Med       Date:  2009-04-15       Impact factor: 2.373

6.  Change-Plane Analysis for Subgroup Detection and Sample Size Calculation.

Authors:  Ailin Fan; Rui Song; Wenbin Lu
Journal:  J Am Stat Assoc       Date:  2017-04-13       Impact factor: 5.033

7.  Protocolized Care for Early Septic Shock (ProCESS) statistical analysis plan.

Authors:  Francis Pike; Donald M Yealy; John A Kellum; David T Huang; Amber E Barnato; Tammy L Eaton; Derek C Angus; Lisa A Weissfeld
Journal:  Crit Care Resusc       Date:  2013-12       Impact factor: 2.159

8.  Evaluating marker-guided treatment selection strategies.

Authors:  Roland A Matsouaka; Junlong Li; Tianxi Cai
Journal:  Biometrics       Date:  2014-04-29       Impact factor: 2.571

9.  Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.

Authors:  Olivia Pagani; Shari Gelber; Edda Simoncini; Monica Castiglione-Gertsch; Karen N Price; Richard D Gelber; Stig B Holmberg; Diana Crivellari; John Collins; Jurij Lindtner; Beat Thürlimann; Martin F Fey; Elizabeth Murray; John F Forbes; Alan S Coates; Aron Goldhirsch
Journal:  Breast Cancer Res Treat       Date:  2008-10-25       Impact factor: 4.872

10.  Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer.

Authors:  Manish A Shah; Yoon-Koo Kang; Peter C Thuss-Patience; Atsushi Ohtsu; Jaffer A Ajani; Eric Van Cutsem; Silke Hoersch; Marie-Laurence Harle-Yge; Sanne Lysbet de Haas
Journal:  Gastric Cancer       Date:  2019-01-31       Impact factor: 7.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.